TAF/FTC

Phase 1Small molecule

GGöteborg University

TAF/FTC is one of 4 small molecule programs targeting Mild Cognitive Impairment (MCI). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mild Cognitive Impairment (MCI)Active, not recruiting

Mild Cognitive Impairment (MCI)Phase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Mild Cognitive Impairment (MCI)

#DrugCompanyPhaseTrials

Emtriva

Gilead

Phase 1

1 2

KDS2010

NNeuroBiogen Co., Ltd

Phase 2

1 3

Gamma- Glutamylcysteine

PPravat Mandal

Phase 1

1 4

TAF/FTC

GGöteborg University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tenofovir1 trial

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

Completed·GGöteborg University·Phase 4·NCT02771054·22 enrolled

Mild Cognitive Impairment (MCI)1 trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Emtricitabine and Descovy in Patients With Mild Cognitive Impairment.

Active, not recruiting·NNational University Hospital, Singapore·Phase 1·NCT07210528·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TAF/FTC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAF/FTC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAF/FTC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Göteborg University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGöteborg University

TAF/FTC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tenofovir1 trial

Mild Cognitive Impairment (MCI)1 trial

References

Drug Info

Quick Facts

Related News